Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23419111 | 0.93 | KMT2A (0.52) | KMT2AMEN1ATMHPGDPOLB | |
| SCHEMBL23389188 | 0.93 | KMT2A (0.52) | KMT2AMEN1ATMHPGDPOLB | |
| SCHEMBL23419215 | 0.79 | EPHX2 (0.63) | POLBEPHX2 | |
| SCHEMBL23418851 | 0.79 | EPHX2 (0.63) | POLBEPHX2 | |
| SCHEMBL23389214 | 0.77 | EPHX2 (0.42) | EPHX2HRH3 | |
| SCHEMBL23389211 | 0.77 | EPHX2 (0.42) | EPHX2HRH3 | |
| SCHEMBL23389124 | 0.73 | EPHX2 (0.46) | POLBKDM4EEPHX2ALDH1A1 | |
| SCHEMBL23389123 | 0.73 | EPHX2 (0.46) | POLBKDM4EEPHX2ALDH1A1 | |
| SCHEMBL25991218 | 0.72 | KMT2A (0.53) | KMT2AMEN1ATMHPGDPOLB | |
| SCHEMBL23389238 | 0.72 | KMT2A (0.60) | KMT2AMEN1ATMHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KMT2A 4587/4885MEN1 4223/4885ATM 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.